Search
Indoprofen
go.drugbank.com/drugs/DB08951ApprovedWithdrawnFollowing reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.
(R)-acetoin
go.drugbank.com/drugs/DB04364ExperimentalIt is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
(S)-acetoin
go.drugbank.com/drugs/DB02788ExperimentalIt is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Aetiocholanolone
go.drugbank.com/drugs/DB02854ExperimentalEtiocholanolone is a major metabolite of testosterone and androstenedione in many mammalian species including humans. It is excreted in the urine. [PubChem]
MORAb-066
go.drugbank.com/drugs/DB17347InvestigationalMORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
Human Embryonic Stem Cell-derived M Cell
go.drugbank.com/drugs/DB15734InvestigationalIMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. … CAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection.
Magnesium orotate
go.drugbank.com/drugs/DB13786ExperimentalMagnesium orotate is a magnesium salt of orotic acid and is poorly soluble in water. It is a source of magnesium and is used as a mineral supplement to treat Mg deficiency. … It also exhibits antioxidant properties, since it is a key intermediate in the biosynthetic pathway of pyrimidines that promotes the synthesis of enzymes which act as free radical scavengers.
Posizolid
go.drugbank.com/drugs/DB04850InvestigationalIn July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though … Posizolid (AZD2563) is an oxazolidinone antibiotic.
AZD0947
go.drugbank.com/drugs/DB04848ExperimentalAs of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.